Latest Commercialisation News

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

4DMedical has expanded its partnership with Philips, securing a US$10 million order commitment to distribute its CT – VQ™ lung imaging technology across North America, aiming to transform pulmonary diagnostics.

Talga Group has applied for a SEK 1.1 billion grant to fund a commercial-scale battery anode plant in Sweden, complementing existing EU funding and securing strong customer interest.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Optiscan Imaging Ltd has initiated Australia’s first intra-operative head and neck cancer imaging study using its advanced InVue® and InForm™ devices, aiming to enhance surgical precision and support FDA regulatory submissions.

ABx Group has produced its maiden mixed rare earth carbonate from Tasmania’s Deep Leads deposit, boasting dysprosium and terbium contents far exceeding peers and commanding a premium basket price.

Lindian Resources confirms a high-grade, ultra-low-radiation rare earth carbonate product from its Kangankunde project, achieving 97% recovery of critical neodymium and praseodymium. The breakthrough promises simpler processing and competitive operating costs.

Environmental Clean Technologies Limited has appointed renowned PFAS litigation expert Robert Bilott to its Advisory Board, aiming to accelerate commercialisation of its innovative remediation technology. This strategic move coincides with shareholder approval of ECT’s acquisition of Terrajoule Pty Ltd.

Environmental Clean Technologies (ECT) has taken a major step in tackling the global PFAS contamination crisis by acquiring Rice University’s Flash Joule Heating technology and appointing renowned PFAS attorney Robert Bilott to its advisory board.

Imagion Biosystems is set to submit its Investigational New Drug application for the MagSense® HER2 breast cancer imaging agent in December 2025, paving the way for a Phase 2 clinical trial in early 2026. Collaboration with Wayne State University has refined the trial design, promising improved patient safety and diagnostic precision.

Wide Open Agriculture shakes up its leadership with a new board appointment and plans to recruit a CEO experienced in scaling plant protein businesses, signaling a strategic push to globalise its lupin protein technology.